দেশ: জর্ডন
ভাষা: ইংরেজি
সূত্র: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)
Pregabalin 300 mg
الشركة المتحدة لصناعة الأدوية - United Pharmaceutical Manufacturing Co. Ltd.
N03AX16
Pregabalin 300 mg
300 mg
60
UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN (الاردن)
58.33 :سعر الجمهور + الضريبة
TID = Three divided doses BID = Two divided doses * Total daily dose (mg/day) should be divided as in- dicated by dose regimen to provide mg/dose + Supplementary dose is a single additional dose USE IN PATIENTS WITH HEPATIC IMPAIRMENT No dose adjustment is required for patients with hepatic impairment. PEDIATRIC POPULATION The safety and efficacy of NEO GABA ® in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. No data are available. Use in the elderly (over 65 years of age) Elderly patients may require a dose reduction of pregabalin due to a decreased renal function. METHOD OF ADMINISTRATION NEO GABA ® may be taken with or without food. NEO GABA ® is for oral use only. CONTRAINDICATIONS: - Hypersensitivity to the active substance or to any of the excipients. - Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy. PRECAUTIONS: Misuses abuse potential or dependence: Cases of misuse, abuse and dependence have been re- ported. Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of pregabalin misuse, abuse or dependence (development of tolerance, dose escalation, drug-seeking behavior have been reported). IMPORTANT IDENTIFIED RISKS: - Some patients treated with pregabalin have expe- rienced, elevated, mood (Euphoria). - Before taking pregabalin, patients should tell their doctor if they have a history of alcoholism or drug dependence. Patients should let their doctor know if they think they need more of the medicine than has been prescribed for them. DIABETIC PATIENTS: In accordance with current clini- cal practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypo- glycemic medicinal products. HYPERSENSITIVITY REACTIONS: There have been re- ports of hypersensitivity in patients shortly after ini- tiation of treatment with NEO GABA ® . Adverse re- actions included skin redness, blisters, hives, rash, dyspnea, an সম্পূর্ণ নথি পড়ুন